NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth
NeoGenomics (NEO) reported Q2 2026 revenue of $201.7 million, up 11% year over year, with clinical revenue up 14% and NGS revenue up 26%. Adjusted gross margin rose to 48.1% and adjusted EBITDA increased to $14.4 million. Nonclinical/pharma revenue fell 26%. 2026 guidance was raised to $802-$806 million revenue and $56-$58 million adjusted EBITDA.
How this was made
The 30-second read
Why it matters
Guidance increases for 2026 revenue and adjusted EBITDA, plus adjusted gross margin expansion, are the primary catalysts for repricing. Offsetting risks include pharma revenue decline, contract exit effects on volume, and uncertainty around private insurer coverage timing for new tests.
Market read
Traders can update models and positioning based on the raised 2026 revenue ($802M-$806M) and adjusted EBITDA ($56M-$58M) guidance, while monitoring pharma and reimbursement-related risks.
What to watch
Nonclinical pharma is only ~5% of revenue, but percentage declines can still reflect underlying demand softness; also, exit from a high-volume, low-value contract and insurer coverage timing could affect future test volumes and cash conversion.
Background
The article summarizes NeoGenomics Q2 2026 results and earnings call Q&A, including segment performance (clinical, NGS, nonclinical/pharma) and full-year guidance changes.
Ticker impact
NeoGenomics reported Q2 revenue of $201.7M (+11% YoY) and raised 2026 revenue guidance to $802M-$806M.
Likely near-term positive bias for NEO as guidance raises the baseline, with volatility around pharma and reimbursement-related uncertainties.
The article discloses multiple quantitative upgrades (revenue and EBITDA guidance) plus margin expansion, which typically supports valuation, while it also highlights specific offsetting headwinds (pharma revenue down 26%, insurer coverage timing uncertainty).
Market effects
Signals continued strength in NGS demand and pricing/mix initiatives for oncology diagnostics, while pharma services remain a drag.
No specific regional impact described beyond US-listed company results.
Limited global read-through; focus is on company-specific guidance and reimbursement dynamics.
Counterpoint
The guidance raise may be driven by clinical and NGS momentum, while pharma underperformance and reimbursement timing uncertainty could cause second-half or 2027 variability.
Key entities
- companyNeoGenomics Inc
Reports Q2 2026 results and raises 2026 revenue and adjusted EBITDA guidance; highlights clinical and NGS strength alongside pharma weakness and reimbursement uncertainty.
- executiveTony Zook
CEO quoted on NGS durability, pharma segment outlook, and reimbursement/indication milestones.
- executiveAbhishek Jain
CFO quoted on guidance drivers, AUP sustainability, and segment dynamics.
- executiveWarren Stone
President, Clinical Services, quoted on RaDaR ST indication reimbursement milestones and addressable market expansion.
